Double-strand break repair: HR versus end joining
A break through both strands of DNA is the most dangerous lesion a cell faces. Two crews compete to fix it: homologous recombination copies the answer from the sister chromosome (accurate, needs BRCA), while end joining simply glues the ends (fast, sloppy). Which crew wins decides whether PARP inhibitors and radiation kill the cell.
The MRN complex (MRE11-RAD50-NBS1) senses the break and activates ATM, which phosphorylates H2AX, CHK2 and p53. Pathway choice is set by resection: 53BP1-RIF1-Shieldin protect ends and favour classical NHEJ (Ku70/80, DNA-PKcs, Artemis, XRCC4-LIG4), dominant in G1 and used by radiation-damaged cells; BRCA1-CtIP promote resection in S/G2, RPA coats the single strand, and PALB2-BRCA2 load RAD51 to form a filament that invades the sister chromatid for accurate copying. Polymerase-theta-mediated end joining (TMEJ) is the backup that leaves microhomology-flanked deletions, the scar of HR deficiency. BRCA1/2, PALB2, RAD51C/D and ATM loss define HRD; such tumours cannot repair replication-associated breaks caused by PARP trapping, platinum crosslinks or topoisomerase poisons, and depend on POLQ and ATR. Reversion mutations, 53BP1/Shieldin loss (restoring resection in BRCA1-null cells), and fork protection restore HR under PARP-inhibitor pressure. DNA-PK inhibitors radiosensitise; ATM loss sensitises to ATR inhibition.
In one picture
A torn page. The careful archivist (HR) fetches the twin copy from the shelf and transcribes it letter for letter; the hurried clerk (NHEJ) tapes the two halves together, losing a few words. Tumours missing the archivist survive on the clerk, so anything that adds more torn pages (PARP inhibitors, platinum, radiation) buries them.
Diagram
top- PARP inhibitors (olaparib, niraparib, rucaparib, talazoparib) in BRCA/HRD ovarian, breast, prostate, pancreatic cancer
- Platinum chemotherapy and radiation add breaks HR-deficient cells cannot fix
- POLQ inhibitors (novobiocin analogues), ATR inhibitors after ATM loss, DNA-PK inhibitors with radiotherapy (trials)
- HRD testing (genomic scars, BRCA sequencing) and RAD51 foci assays select patients; reversion mutations detected in ctDNA flag resistance
Pages like this
not linked directly; found by shared links- PathwayThe p53 network (guardian of the genome)
Shares WEE1, ATR, DNA replication stress, Synthetic lethality: paired dependencies and the tags mechanism, mechanics-atlas.
- PathwayDrivers, passengers & the two-hit model
Shares Hereditary cancer syndromes, Mutagenesis & mutational signatures, Synthetic lethality, Germline vs somatic mutations and the tags mechanism, mechanics-atlas.
- PathwayMismatch repair & microsatellite instability
Shares Mutagenesis & mutational signatures, Mutational signature, Synthetic lethality: paired dependencies, Synthetic lethality approaches and the tags mechanism, mechanics-atlas.
- PathwayDNA replication & origin licensing
Shares ATR, DNA replication stress, DNA damage response & homologous recombination, Platinum agents and the tags mechanism, mechanics-atlas.
- PathwayThe cell-cycle engine (cyclins & CDKs)
Shares WEE1, DNA replication stress, Ovarian cancer and the tags mechanism, mechanics-atlas.
- PathwayThe cancer-immunity cycle
Shares cGAS–STING innate sensing, SBRT / SABR (stereotactic radiotherapy) and the tags mechanism, mechanics-atlas.
- PathwayOrgan tropism: seed and soil
Shares SBRT / SABR (stereotactic radiotherapy), Ovarian cancer, Prostate cancer and the tags mechanism, mechanics-atlas.
- PathwayThe blood–brain barrier & brain metastasis
Shares cGAS–STING innate sensing, SBRT / SABR (stereotactic radiotherapy) and the tags mechanism, mechanics-atlas.